Bluefish raises approximately SEK 28 million in new capital

Bluefish Pharmaceuticals has completed a successful capital raising of approximately SEK 28 million in new capital from a number of new investors. The new capital will be used to continue the European expansion and confirms a continued strong interest for Bluefish and its business model

Nordea Bank has acted financial adviser.

For further information:
Bluefish Pharmaceuticals
Karl Karlsson, President and CEO, tel +46 8 679 50 70
Susanna Urdmark, Executive VP, Global Product Strategy, tel +46 8 679 50 70
Bluefish Pharmaceuticals

Bluefish Pharmaceuticals AB is a Swedish pharmaceutical company that licenses, develops, manufactures and markets mainly generic pharmaceutical products. Low prices are maintained through efficient production and distribution. Bluefish has a wholly‐owned subsidiary in Chennai, India, focusing on product development and production. The company is owned by its founder Karl Karlsson, together with a number of investment funds and private investors.